首页 > 最新文献

Pharmaceutical Biology最新文献

英文 中文
Hyaluronic acid-engineered milk extracellular vesicles to target triple negative breast cancer through CD44. 透明质酸工程牛奶细胞外囊泡通过CD44靶向三阴性乳腺癌。
IF 4.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-12-01 Epub Date: 2025-06-05 DOI: 10.1080/13880209.2025.2511807
Filipa A Soares, Beatriz Salinas, Salette Reis, Cláudia Nunes

Context: Cancer therapy remains a challenge in healthcare, particularly in the context of triple-negative breast cancer (TNBC), where targeted therapies are still scarce.

Objective: Addressing this issue, our study explores a novel targeting approach using small extracellular vesicles (sEVs) isolated from cow milk, functionalized with hyaluronic acid (HA) to target the overexpressed cluster of differentiation 44 (CD44) cell surface receptor in TNBC cells.

Materials & methods: A method for isolating sEVs from cow milk was optimized, and the obtained sEVs were fully characterized in terms of size, morphology, and protein markers. Subsequently, milk-derived sEVs were covalently bound with HA of varying molecular weights (MW, 20-60 kDa, 250 kDa, 1000-1600 kDa) and binding and internalization dynamics were investigated. Breast cancer cell lines, MDA-MB-231 (TNBC and CD44+) and MCF-7 (CD44-), were used as in vitro models to evaluate CD44 selectivity.

Results: The binding and internalization studies unveiled enhanced selectivity of functionalized sEVs for CD44-overexpressing cells compared to non-functionalized sEVs. Notably, higher MW HA exhibited enhanced binding capacity, with partial internalization occurring through CD44 endocytic mechanisms.

Discussion and conclusion: In summary, this work introduces a sEVs isolation method and sheds light on the role of HA MW in enhancing cellular uptake of CD44 overexpressing cancer cells.

背景:癌症治疗在医疗保健中仍然是一个挑战,特别是在三阴性乳腺癌(TNBC)的背景下,靶向治疗仍然很少。为了解决这一问题,我们的研究探索了一种新的靶向方法,利用从牛奶中分离的细胞外小泡(sev),用透明质酸(HA)功能化,靶向TNBC细胞中过表达的CD44细胞表面受体。材料与方法:优化了从牛奶中分离sev的方法,并对所获得的sev进行了大小、形态和蛋白标记的表征。随后,牛奶衍生的sev与不同分子量(MW, 20-60 kDa, 250 kDa, 1000-1600 kDa)的HA共价结合,并研究了结合和内化动力学。以乳腺癌细胞系MDA-MB-231 (TNBC和CD44+)和MCF-7 (CD44-)作为体外模型,评估CD44的选择性。结果:结合和内化研究表明,与非功能化sev相比,功能化sev对cd44过表达细胞的选择性增强。值得注意的是,高分子量HA表现出增强的结合能力,通过CD44内吞机制发生部分内化。讨论和结论:总之,本工作介绍了一种sev分离方法,并阐明了HA MW在增强过表达CD44的癌细胞的细胞摄取中的作用。
{"title":"Hyaluronic acid-engineered milk extracellular vesicles to target triple negative breast cancer through CD44.","authors":"Filipa A Soares, Beatriz Salinas, Salette Reis, Cláudia Nunes","doi":"10.1080/13880209.2025.2511807","DOIUrl":"10.1080/13880209.2025.2511807","url":null,"abstract":"<p><strong>Context: </strong>Cancer therapy remains a challenge in healthcare, particularly in the context of triple-negative breast cancer (TNBC), where targeted therapies are still scarce.</p><p><strong>Objective: </strong>Addressing this issue, our study explores a novel targeting approach using small extracellular vesicles (sEVs) isolated from cow milk, functionalized with hyaluronic acid (HA) to target the overexpressed cluster of differentiation 44 (CD44) cell surface receptor in TNBC cells.</p><p><strong>Materials & methods: </strong>A method for isolating sEVs from cow milk was optimized, and the obtained sEVs were fully characterized in terms of size, morphology, and protein markers. Subsequently, milk-derived sEVs were covalently bound with HA of varying molecular weights (MW, 20-60 kDa, 250 kDa, 1000-1600 kDa) and binding and internalization dynamics were investigated. Breast cancer cell lines, MDA-MB-231 (TNBC and CD44+) and MCF-7 (CD44-), were used as <i>in vitro</i> models to evaluate CD44 selectivity.</p><p><strong>Results: </strong>The binding and internalization studies unveiled enhanced selectivity of functionalized sEVs for CD44-overexpressing cells compared to non-functionalized sEVs. Notably, higher MW HA exhibited enhanced binding capacity, with partial internalization occurring through CD44 endocytic mechanisms.</p><p><strong>Discussion and conclusion: </strong>In summary, this work introduces a sEVs isolation method and sheds light on the role of HA MW in enhancing cellular uptake of CD44 overexpressing cancer cells.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"411-427"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis. 中药黄酮抗抑郁活性的meta分析。
IF 3.9 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-12-01 Epub Date: 2025-02-25 DOI: 10.1080/13880209.2025.2467374
Qing Wang, Youyuan Lu, Xue Mi, Caiyan Yang, Wei Ma, Changbo Xia, Hanqing Wang

Context: Flavones, the key active components in Traditional Chinese Medicine (TCM), have demonstrated antidepressant activity. Given the numerous animal studies conducted, a systematic analysis is essential to provide a valuable reference for future research.

Object: This study investigated the antidepressant activity of flavones based on animal models and summarized the underlying mechanisms.

Methods: We systematically searched 7 bibliographic Databases as of August 12, 2023, such as Web of Science, PubMed, China National Knowledge Infrastructure, etc. The meta-analysis was performed using either the random or fixed-effect model, supplemented by trial sequential analysis (TSA). The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess the quality of evidence.

Results: A total of 25 studies involving 458 mice were included, identifying five flavones (baicalin, baicalein, apigenin, luteolin, vitexin) with antidepressant activity. Compared to the control group, flavones significantly reduced immobility time in forced swimming and tail suspension tests. Flavones also decreased serum and hippocampal levels of interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α), reduced nuclear factor kappa B (NF-κB) levels, and increased brain-derived neurotrophic factor (BDNF) levels. Relative to the positive group, flavones raised IL-6, sucrose preference rate, and corticosterone (CORT) levels, with no significant differences in other factors. The TSA showed the efficacy of flavones for treating depression with adequate 'information size' for the primary outcome.

Conclusions: The results demonstrate that flavones exert protective effects against depression in mice, primarily by stimulating neurotrophic factors and modulating inflammatory pathways. These findings emphasize their potential as promising candidates for the development of novel antidepressant therapies.

背景:黄酮是中药中的重要活性成分,具有抗抑郁作用。鉴于进行了大量的动物研究,系统的分析是必要的,为未来的研究提供有价值的参考。目的:通过动物实验研究黄酮类化合物的抗抑郁作用,并对其机制进行总结。方法:系统检索截至2023年8月12日的Web of Science、PubMed、China National Knowledge Infrastructure等7个文献数据库。meta分析采用随机或固定效应模型,并辅以试验序列分析(TSA)。采用推荐、评估、发展和评价分级(GRADE)方法评估证据质量。结果:共纳入25项研究,458只小鼠,鉴定出黄芩苷、黄芩苷、芹菜素、木犀草素、牡荆素5种黄酮具有抗抑郁活性。与对照组相比,黄酮在强迫游泳和悬尾试验中显著减少了静止时间。黄酮还能降低血清和海马白介素(IL)-1β和肿瘤坏死因子-α (TNF-α)水平,降低核因子κB (NF-κB)水平,升高脑源性神经营养因子(BDNF)水平。与阳性组相比,黄酮提高了IL-6、蔗糖偏好率和皮质酮(CORT)水平,其他因素无显著差异。TSA显示了黄酮类药物治疗抑郁症的有效性,并为主要结果提供了足够的“信息大小”。结论:黄酮主要通过刺激神经营养因子和调节炎症通路对小鼠抑郁具有保护作用。这些发现强调了它们作为开发新型抗抑郁疗法的有希望的候选药物的潜力。
{"title":"Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis.","authors":"Qing Wang, Youyuan Lu, Xue Mi, Caiyan Yang, Wei Ma, Changbo Xia, Hanqing Wang","doi":"10.1080/13880209.2025.2467374","DOIUrl":"10.1080/13880209.2025.2467374","url":null,"abstract":"<p><strong>Context: </strong>Flavones, the key active components in Traditional Chinese Medicine (TCM), have demonstrated antidepressant activity. Given the numerous animal studies conducted, a systematic analysis is essential to provide a valuable reference for future research.</p><p><strong>Object: </strong>This study investigated the antidepressant activity of flavones based on animal models and summarized the underlying mechanisms.</p><p><strong>Methods: </strong>We systematically searched 7 bibliographic Databases as of August 12, 2023, such as Web of Science, PubMed, China National Knowledge Infrastructure, etc. The meta-analysis was performed using either the random or fixed-effect model, supplemented by trial sequential analysis (TSA). The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess the quality of evidence.</p><p><strong>Results: </strong>A total of 25 studies involving 458 mice were included, identifying five flavones (baicalin, baicalein, apigenin, luteolin, vitexin) with antidepressant activity. Compared to the control group, flavones significantly reduced immobility time in forced swimming and tail suspension tests. Flavones also decreased serum and hippocampal levels of interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α), reduced nuclear factor kappa B (NF-κB) levels, and increased brain-derived neurotrophic factor (BDNF) levels. Relative to the positive group, flavones raised IL-6, sucrose preference rate, and corticosterone (CORT) levels, with no significant differences in other factors. The TSA showed the efficacy of flavones for treating depression with adequate 'information size' for the primary outcome.</p><p><strong>Conclusions: </strong>The results demonstrate that flavones exert protective effects against depression in mice, primarily by stimulating neurotrophic factors and modulating inflammatory pathways. These findings emphasize their potential as promising candidates for the development of novel antidepressant therapies.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"156-169"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review. 黄芪甲苷在心血管疾病动物模型中的抗纤维化作用及其机制综述
IF 4.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-12-01 Epub Date: 2025-04-22 DOI: 10.1080/13880209.2025.2488994
Shiyu Zhang, Shijie Li, Xue Li, Chen Wan, Lin Cui, Youping Wang

Context: Myocardial fibrosis is a common manifestation of end-stage cardiovascular disease, but there is a lack of means to reverse fibrosis. Astragaloside IV (AS-IV), the major active component of Astragalus membranaceus Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease.

Objective: This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV.

Methods: PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE.

Results and conclusion: AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.

背景:心肌纤维化是终末期心血管疾病的常见表现,但缺乏逆转纤维化的手段。黄芪甲苷(Astragaloside IV, AS-IV)是黄芪的主要活性成分。蚕豆科植物,具有多种生物活性,对心血管疾病有有益作用。目的:本系统综述旨在总结AS-IV在动物模型(大鼠或小鼠)中的抗纤维化作用及其机制,为AS-IV的临床应用提供可能的方向。方法:检索PubMed、EMBASE、Web of Science、中国知网(CNKI)、万方数据库、中国医学信息网(sinmed)自建库至2024年12月31日。提取并总结纳入研究的以下特点:动物模型、给药途径、剂量/浓度、测量指标及可能机制。纳入研究的质量采用sycle的10项量表进行评估。结果和结论:在纳入分析的24项符合条件的研究中,AS-IV是一种有希望的多靶点心肌纤维化治疗候选药物。本系统综述首次全面评价AS-IV在异质心血管疾病动物模型中的抗纤维化机制,包括心肌梗死、高血压、缺血再灌注损伤和心肌炎。AS-IV抗纤维化作用的机制可能包括胶原代谢、抗凋亡、抗炎、抗焦亡、抗氧化、改善线粒体功能、调节衰老等。目前的证据仍然是临床前的,在毒理学概况、人体安全阈值和临床不良反应数据方面存在重大差距。未来的研究必须整合强有力的毒理学评估、优化的联合疗法和适应性临床试验,以验证转化潜力。
{"title":"Anti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review.","authors":"Shiyu Zhang, Shijie Li, Xue Li, Chen Wan, Lin Cui, Youping Wang","doi":"10.1080/13880209.2025.2488994","DOIUrl":"10.1080/13880209.2025.2488994","url":null,"abstract":"<p><strong>Context: </strong>Myocardial fibrosis is a common manifestation of end-stage cardiovascular disease, but there is a lack of means to reverse fibrosis. Astragaloside IV (AS-IV), the major active component of <i>Astragalus membranaceus</i> Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease.</p><p><strong>Objective: </strong>This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV.</p><p><strong>Methods: </strong>PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE.</p><p><strong>Results and conclusion: </strong>AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"250-263"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genotoxic assessment of a Cannabis sativa L. extract. 大麻提取物的基因毒性评价。
IF 3.9 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-04-29 Epub Date: 2025-05-06 DOI: 10.1080/13880209.2025.2499075
Mark J Tallon, Robert B Child, Jason L Blum

Context: As a naturally occurring terpenoid found in Cannabis sativa L. (Cannabaceae), cannabidiol (CBD) has gained public and industry interest for the purposes of personal well-being as a foodstuff and pharmaceutical. Despite a number of publications on CBD toxicology, many have significant limitations, especially those relating to genotoxicity. These include poor characterization of the CBD extract and/or lack rigor in conforming to accepted regulatory guidelines and best practice. A number of regulatory agencies have highlighted these issues and requested additional genotoxicity data to help ensure the safe use of CBD.

Objective: To provide insights into the genotoxicity of a CBD isolate and its lipid carrier.

Materials and methods: We have conducted an in vitro mammalian cell micronucleus (OECD 487) and a bacterial reverse mutagenicity assay (Ames test) (OECD 471) in a CBD isolate (97% > CBD) with its carrier.

Results: The samples tested were non-mutagenic, as determined in the Ames test. The in vitro micronucleus assay conducted was negative for genotoxicity, with no statistically significant increases in the incidences of micronucleated cells observed at any dose compared to negative controls.

Conclusions: These studies confirm that this CBD rich isolate in combination with its carrier, are unlikely to post any genotoxic hazard at exposure levels expected in foods.

背景:大麻二酚(CBD)作为一种天然存在的萜类化合物,在大麻科(大麻科)中被发现,作为一种食品和药物,大麻二酚(CBD)已经获得了公众和行业的兴趣,用于个人福祉。尽管有许多关于CBD毒理学的出版物,但许多出版物都有明显的局限性,特别是与遗传毒性有关的出版物。这些包括CBD提取物的特征不佳和/或缺乏严格遵守公认的监管准则和最佳实践。一些监管机构强调了这些问题,并要求提供更多的遗传毒性数据,以帮助确保CBD的安全使用。目的:了解CBD分离物及其脂质载体的遗传毒性。材料和方法:我们对CBD分离物(97% > CBD)及其载体进行了体外哺乳动物细胞微核(OECD 487)和细菌反向诱变试验(Ames试验)(OECD 471)。结果:在Ames试验中,检测的样品是非诱变的。体外微核试验的遗传毒性为阴性,与阴性对照相比,在任何剂量下都没有观察到微核细胞发生率的统计学显著增加。结论:这些研究证实,这种富含CBD的分离物与其载体结合在一起,不太可能在食品暴露水平下产生任何遗传毒性危害。
{"title":"Genotoxic assessment of a <i>Cannabis sativa</i> L. extract.","authors":"Mark J Tallon, Robert B Child, Jason L Blum","doi":"10.1080/13880209.2025.2499075","DOIUrl":"https://doi.org/10.1080/13880209.2025.2499075","url":null,"abstract":"<p><strong>Context: </strong>As a naturally occurring terpenoid found in <i>Cannabis sativa</i> L. (Cannabaceae), cannabidiol (CBD) has gained public and industry interest for the purposes of personal well-being as a foodstuff and pharmaceutical. Despite a number of publications on CBD toxicology, many have significant limitations, especially those relating to genotoxicity. These include poor characterization of the CBD extract and/or lack rigor in conforming to accepted regulatory guidelines and best practice. A number of regulatory agencies have highlighted these issues and requested additional genotoxicity data to help ensure the safe use of CBD.</p><p><strong>Objective: </strong>To provide insights into the genotoxicity of a CBD isolate and its lipid carrier.</p><p><strong>Materials and methods: </strong>We have conducted an <i>in vitro</i> mammalian cell micronucleus (OECD 487) and a bacterial reverse mutagenicity assay (Ames test) (OECD 471) in a CBD isolate (97% > CBD) with its carrier.</p><p><strong>Results: </strong>The samples tested were non-mutagenic, as determined in the Ames test. The <i>in vitro</i> micronucleus assay conducted was negative for genotoxicity, with no statistically significant increases in the incidences of micronucleated cells observed at any dose compared to negative controls.</p><p><strong>Conclusions: </strong>These studies confirm that this CBD rich isolate in combination with its carrier, are unlikely to post any genotoxic hazard at exposure levels expected in foods.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"357-363"},"PeriodicalIF":3.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive analysis of the potential mechanism of gansui in blocking non-small cell lung cancer progression. 肝遂阻断非小细胞肺癌进展的潜在机制综合分析。
IF 3.9 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-02-25 Epub Date: 2025-03-03 DOI: 10.1080/13880209.2025.2471844
Xiaoxu Yang, Wenlan Li

Context: Gansui [Euphorbia kansui T. N. Liou ex S.B.Ho (Euphorbiaceae)] has been reported to inhibit the proliferation of non-small cell lung cancer (NSCLC) cells; however, its underlying pharmacological mechanism remains unclear.

Objective: To investigate the potential effects and mechanisms of Gansui in blocking NSCLC progression.

Materials and methods: The targets of Gansui's components and NSCLC-related targets were obtained through public database and published studies. Functional enrichment analysis was performed using the clusterProfiler R package. STRING database was used for protein-protein interaction analysis. CytoHubba plugin was applied to get the hub genes. Molecular docking was applied to assess the binding affinities between the hub targets and the crucial components. Kidjolanin was used to treat A549 and NCI-H1385, and its effects on cell viability, sensitivity of paclitaxel and expression levels of hub genes were investigated by cell counting kit-8 assay, flow cytometry and qPCR.

Results: A total of 16 Gansui active ingredients and 337 targets were collected, of which 298 targets overlapped with NSCLC-related genes. STAT3, EGFR, GRB2, AKT2, AKT3 and PIK3CA were identified as hub genes. The components in Gansui, including kidjoranin 3-O-β-digitoxopyranoside, cynotophylloside B, 13-Oxyingenol-dodecanoate, and kidjolanin had good binding affinity with the hub targets. Kidjolanin inhibited the viability of NSCLC cells, promoted apoptosis and inhibited the expression of hub genes. Kidjolanin also enhanced the proliferation inhibition and apoptosis of NSCLC cells induced by paclitaxel.

Discussion and conclusion: Gansui exerts anti-NSCLC effects via multiple downstream targets, implying its potential in NSCLC treatment.

背景:甘穗[euphorbibia kansui T. N. Liou ex s.b.h ho (Euphorbiaceae)]有报道能抑制非小细胞肺癌(NSCLC)细胞的增殖;然而,其潜在的药理机制尚不清楚。目的:探讨肝遂在阻断非小细胞肺癌进展中的潜在作用及其机制。材料和方法:通过公开数据库和已发表的研究获得甘穗各成分的靶点和nsclc相关靶点。功能富集分析使用clusterProfiler R包进行。蛋白-蛋白互作分析采用STRING数据库。应用CytoHubba插件获取中心基因。分子对接用于评估枢纽靶点与关键组分之间的结合亲和力。采用细胞计数试剂盒-8、流式细胞术和qPCR检测Kidjolanin对A549和NCI-H1385细胞活力、紫杉醇敏感性和枢纽基因表达水平的影响。结果:共收集甘穗有效成分16种,靶点337个,其中与nsclc相关基因重叠的靶点298个。中心基因为STAT3、EGFR、GRB2、AKT2、AKT3和PIK3CA。甘穗中的木贼苷3-O-β-洋地黄氧吡喃苷、cynotophyloside B、13-氧辛醇十二烷酸酯和木贼苷与枢纽靶点具有良好的结合亲和力。Kidjolanin抑制NSCLC细胞活力,促进细胞凋亡,抑制中枢基因表达。Kidjolanin还能增强紫杉醇诱导的非小细胞肺癌细胞的增殖抑制和凋亡。讨论与结论:肝遂通过多个下游靶点发挥抗NSCLC作用,提示其在NSCLC治疗中的潜力。
{"title":"Comprehensive analysis of the potential mechanism of gansui in blocking non-small cell lung cancer progression.","authors":"Xiaoxu Yang, Wenlan Li","doi":"10.1080/13880209.2025.2471844","DOIUrl":"10.1080/13880209.2025.2471844","url":null,"abstract":"<p><strong>Context: </strong>Gansui [<i>Euphorbia kansui</i> T. N. Liou ex S.B.Ho (Euphorbiaceae)] has been reported to inhibit the proliferation of non-small cell lung cancer (NSCLC) cells; however, its underlying pharmacological mechanism remains unclear.</p><p><strong>Objective: </strong>To investigate the potential effects and mechanisms of Gansui in blocking NSCLC progression.</p><p><strong>Materials and methods: </strong>The targets of Gansui's components and NSCLC-related targets were obtained through public database and published studies. Functional enrichment analysis was performed using the clusterProfiler R package. STRING database was used for protein-protein interaction analysis. CytoHubba plugin was applied to get the hub genes. Molecular docking was applied to assess the binding affinities between the hub targets and the crucial components. Kidjolanin was used to treat A549 and NCI-H1385, and its effects on cell viability, sensitivity of paclitaxel and expression levels of hub genes were investigated by cell counting kit-8 assay, flow cytometry and qPCR.</p><p><strong>Results: </strong>A total of 16 Gansui active ingredients and 337 targets were collected, of which 298 targets overlapped with NSCLC-related genes. <i>STAT3</i>, <i>EGFR</i>, <i>GRB2</i>, <i>AKT2, AKT3</i> and <i>PIK3CA</i> were identified as hub genes. The components in Gansui, including kidjoranin 3-O-β-digitoxopyranoside, cynotophylloside B, 13-Oxyingenol-dodecanoate, and kidjolanin had good binding affinity with the hub targets. Kidjolanin inhibited the viability of NSCLC cells, promoted apoptosis and inhibited the expression of hub genes. Kidjolanin also enhanced the proliferation inhibition and apoptosis of NSCLC cells induced by paclitaxel.</p><p><strong>Discussion and conclusion: </strong>Gansui exerts anti-NSCLC effects <i>via</i> multiple downstream targets, implying its potential in NSCLC treatment.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"170-187"},"PeriodicalIF":3.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sustainable cultivation of phytopharmaceuticals in Baden-Wuerttemberg, Germany: a SWOT analysis and future directions. 德国巴登-符腾堡州植物药可持续种植:SWOT分析及未来发展方向
IF 3.9 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2025-01-22 Epub Date: 2025-02-01 DOI: 10.1080/13880209.2025.2457328
Peter W Heger, Ilka Meinert, Peter Nick, Peter Riedl, Michael Heinrich, Michael Straub

Objectives: The aim of this systematic work is a Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis to select suitable medicinal plants for cultivation in the region of Baden-Wuerttemberg, Germany.

Methods: A systematic SWOT analysis, based on expert assesments and literature research, was performed considering factors like market demand, cultivation conditions, and potential economic benefits.

Results: Medicinal plants have been essential for producing compounds with significant health benefits. However, unsuitable harvesting practices threaten plant species and traditional communities due to loss of knowledge and culture. In response, sustainable cultivation is gaining attention as alternative to wild collection, ensuring both biodiversity conversation and integrity of medicinal products. Three plants - Arnica montana L., Hydrastis canadensis L., and Rheum rhaponticum L. - were identified as particularly suitable due to their high demand and feasibility of their cultivation under local conditions. Conversely, six other plants were deemed less viable due to various challenges, including market competition and harvesting difficulties.

Conclusions: This publication emphasizes the importance of comprehensive planning and analysis in transitioning from wild collection to sustainable cultivation of medicinal plants, highlighting the potential benefits for regional agriculture, conservation efforts, and the pharmaceutical industry. BIOPRO Baden-Württemberg GmbH promotes this approach by fostering a bioeconomy centred on cultivating high-value medicinal plants in the state of Baden-Wuerttemberg, Germany.

目标:这项系统性工作旨在进行优势、劣势、机会和威胁(SWOT)分析,以选择适合在德国巴登-符腾堡州地区种植的药用植物:方法:在专家评估和文献研究的基础上,对市场需求、种植条件和潜在经济效益等因素进行了系统的 SWOT 分析:结果:药用植物是生产对健康有重大益处的化合物的重要原料。然而,由于知识和文化的丧失,不适当的采摘方法威胁着植物物种和传统社区。为此,可持续栽培作为野生采集的替代方法正受到越来越多的关注,它既能确保生物多样性对话,又能确保药用产品的完整性。三种植物--山金车(Arnica montana L.)、水蛭(Hydrastis canadensis L.)和大黄(Rheum rhaponticum L.)--因其需求量大以及在当地条件下种植的可行性而被认为特别适合。相反,其他六种植物由于面临各种挑战,包括市场竞争和收获困难,被认为不太可行:本出版物强调了在药用植物从野生采集过渡到可持续栽培过程中进行全面规划和分析的重要性,突出强调了对地区农业、保护工作和制药业的潜在益处。巴登-符腾堡州 BIOPRO 有限公司通过在德国巴登-符腾堡州培育以种植高价值药用植物为中心的生物经济来推广这种方法。
{"title":"Sustainable cultivation of phytopharmaceuticals in Baden-Wuerttemberg, Germany: a SWOT analysis and future directions.","authors":"Peter W Heger, Ilka Meinert, Peter Nick, Peter Riedl, Michael Heinrich, Michael Straub","doi":"10.1080/13880209.2025.2457328","DOIUrl":"10.1080/13880209.2025.2457328","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this systematic work is a Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis to select suitable medicinal plants for cultivation in the region of Baden-Wuerttemberg, Germany.</p><p><strong>Methods: </strong>A systematic SWOT analysis, based on expert assesments and literature research, was performed considering factors like market demand, cultivation conditions, and potential economic benefits.</p><p><strong>Results: </strong>Medicinal plants have been essential for producing compounds with significant health benefits. However, unsuitable harvesting practices threaten plant species and traditional communities due to loss of knowledge and culture. In response, sustainable cultivation is gaining attention as alternative to wild collection, ensuring both biodiversity conversation and integrity of medicinal products. Three plants - <i>Arnica montana L.</i>, <i>Hydrastis canadensis L.,</i> and <i>Rheum rhaponticum L.</i> - were identified as particularly suitable due to their high demand and feasibility of their cultivation under local conditions. Conversely, six other plants were deemed less viable due to various challenges, including market competition and harvesting difficulties.</p><p><strong>Conclusions: </strong>This publication emphasizes the importance of comprehensive planning and analysis in transitioning from wild collection to sustainable cultivation of medicinal plants, highlighting the potential benefits for regional agriculture, conservation efforts, and the pharmaceutical industry. BIOPRO Baden-Württemberg GmbH promotes this approach by fostering a bioeconomy centred on cultivating high-value medicinal plants in the state of Baden-Wuerttemberg, Germany.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"63 1","pages":"82-88"},"PeriodicalIF":3.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential mechanism of Qinggong Shoutao pill alleviating age-associated memory decline based on integration strategy. 基于整合策略的清宫寿桃丸缓解老年性记忆衰退的潜在机制
IF 3.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-12-01 Epub Date: 2023-12-25 DOI: 10.1080/13880209.2023.2291689
Guiyun Pan, Lijuan Chai, Rui Chen, Qing Yuan, Zhihui Song, Wanying Feng, Jinna Wei, Zhihua Yang, Yuhang Zhang, Guinan Xie, An Yan, Qingbo Lv, Caijun Wang, Yingqiang Zhao, Yi Wang

Context: Qinggong Shoutao Wan (QGSTW) is a pill used as a traditional medicine to treat age-associated memory decline (AAMI). However, its potential mechanisms are unclear.

Objective: This study elucidates the possible mechanisms of QGSTW in treating AAMI.

Materials and methods: Network pharmacology and molecular docking approaches were utilized to identify the potential pathway by which QGSTW alleviates AAMI. C57BL/6J mice were divided randomly into control, model, and QGSTW groups. A mouse model of AAMI was established by d-galactose, and the pathways that QGSTW acts on to ameliorate AAMI were determined by ELISA, immunofluorescence staining and Western blotting after treatment with d-gal (100 mg/kg) and QGSTW (20 mL/kg) for 12 weeks.

Results: Network pharmacology demonstrated that the targets of the active components were significantly enriched in the cAMP signaling pathway. AKT1, FOS, GRIN2B, and GRIN1 were the core target proteins. QGSTW treatment increased the discrimination index from -16.92 ± 7.06 to 23.88 ± 15.94% in the novel location test and from -19.54 ± 5.71 to 17.55 ± 6.73% in the novel object recognition test. ELISA showed that QGSTW could increase the levels of cAMP. Western blot analysis revealed that QGSTW could upregulate the expression of PKA, CREB, c-Fos, GluN1, GluA1, CaMKII-α, and SYN. Immunostaining revealed that the expression of SYN was decreased in the CA1 and DG.

Discussion and conclusions: This study not only provides new insights into the mechanism of QGSTW in the treatment of AAMI but also provides important information and new research ideas for the discovery of traditional Chinese medicine compounds that can treat AAMI.

背景:清宫寿桃丸(QGSTW)是一种用于治疗老年性记忆衰退(AAMI)的传统药物。然而,其潜在机制尚不清楚:本研究阐明了逍遥丸治疗老年性记忆衰退的可能机制:利用网络药理学和分子对接方法确定 QGSTW 缓解 AAMI 的潜在途径。将 C57BL/6J 小鼠随机分为对照组、模型组和 QGSTW 组。用d-gal(100毫克/千克)和QGSTW(20毫升/千克)治疗12周后,通过ELISA、免疫荧光染色和Western印迹法确定QGSTW改善AAMI的作用途径:结果:网络药理学表明,活性成分的靶标在 cAMP 信号通路中明显富集。AKT1、FOS、GRIN2B 和 GRIN1 是核心靶蛋白。QGSTW 治疗可使新定位测试中的辨别指数从 -16.92 ± 7.06% 提高到 23.88 ± 15.94%,使新物体识别测试中的辨别指数从 -19.54 ± 5.71% 提高到 17.55 ± 6.73%。酶联免疫吸附试验表明,QGSTW能提高cAMP的水平。Western印迹分析显示,QGSTW能上调PKA、CREB、c-Fos、GluN1、GluA1、CaMKII-α和SYN的表达。免疫染色显示,SYN在CA1和DG中的表达减少:本研究不仅对QGSTW治疗AAMI的机制有了新的认识,而且为发现可治疗AAMI的中药复方提供了重要信息和新的研究思路。
{"title":"Potential mechanism of Qinggong Shoutao pill alleviating age-associated memory decline based on integration strategy.","authors":"Guiyun Pan, Lijuan Chai, Rui Chen, Qing Yuan, Zhihui Song, Wanying Feng, Jinna Wei, Zhihua Yang, Yuhang Zhang, Guinan Xie, An Yan, Qingbo Lv, Caijun Wang, Yingqiang Zhao, Yi Wang","doi":"10.1080/13880209.2023.2291689","DOIUrl":"10.1080/13880209.2023.2291689","url":null,"abstract":"<p><strong>Context: </strong>Qinggong Shoutao Wan (QGSTW) is a pill used as a traditional medicine to treat age-associated memory decline (AAMI). However, its potential mechanisms are unclear.</p><p><strong>Objective: </strong>This study elucidates the possible mechanisms of QGSTW in treating AAMI.</p><p><strong>Materials and methods: </strong>Network pharmacology and molecular docking approaches were utilized to identify the potential pathway by which QGSTW alleviates AAMI. C57BL/6J mice were divided randomly into control, model, and QGSTW groups. A mouse model of AAMI was established by d-galactose, and the pathways that QGSTW acts on to ameliorate AAMI were determined by ELISA, immunofluorescence staining and Western blotting after treatment with d-gal (100 mg/kg) and QGSTW (20 mL/kg) for 12 weeks.</p><p><strong>Results: </strong>Network pharmacology demonstrated that the targets of the active components were significantly enriched in the cAMP signaling pathway. AKT1, FOS, GRIN2B, and GRIN1 were the core target proteins. QGSTW treatment increased the discrimination index from -16.92 ± 7.06 to 23.88 ± 15.94% in the novel location test and from -19.54 ± 5.71 to 17.55 ± 6.73% in the novel object recognition test. ELISA showed that QGSTW could increase the levels of cAMP. Western blot analysis revealed that QGSTW could upregulate the expression of PKA, CREB, c-Fos, GluN1, GluA1, CaMKII-α, and SYN. Immunostaining revealed that the expression of SYN was decreased in the CA1 and DG.</p><p><strong>Discussion and conclusions: </strong>This study not only provides new insights into the mechanism of QGSTW in the treatment of AAMI but also provides important information and new research ideas for the discovery of traditional Chinese medicine compounds that can treat AAMI.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"62 1","pages":"105-119"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy. Cephaeline通过靶向NRF2促进铁变态反应,从而发挥抗肺癌功效。
IF 3.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-02-09 DOI: 10.1080/13880209.2024.2309891
Peng Chen, Qingxuan Ye, Shang Liang, Linghui Zeng

Context: Cephaeline is a natural product isolated from ipecac (Cephaelis ipecacuanha [Brot.] A. Rich. [Rubiaceae]). It exhibits promising anti-lung cancer activity and ferroptosis induction may be a key mechanism for its anti-lung cancer effect.

Objectives: This study investigates the anti-lung cancer activity and mechanisms of cephaeline both in vitro and in vivo.

Materials and methods: H460 and A549 lung cancer cells were used. The cephaeline inhibition rate on lung cancer cells was detected via a Cell Counting Kit-8 assay after treatment with cephaeline for 24 h. Subsequently, the concentrations of 25, 50 and 100 nM were used for in vitro experiments. In addition, the antitumour effects of cephaeline (5, 10 mg/kg) in vivo were evaluated after 12 d of cephaeline treatment.

Results: Cephaeline showed significant inhibitory effects on lung cancer cells, and the IC50 of cephaeline on H460 and A549 at 24, 48 and 72 h were 88, 58 and 35 nM, respectively, for H460 cells and 89, 65 and 43 nM, respectively, for A549 cells. Meanwhile, we demonstrated that ferroptosis is the key mechanism of cephaeline against lung cancer. Finally, we found that cephaeline induced ferroptosis in lung cancer cells by targeting NRF2.

Discussion and conclusion: We demonstrated for the first time that cephaeline inhibits NRF2, leading to ferroptosis in lung cancer cells. These findings may contribute to the development of innovative therapeutics for lung cancer.

背景:Cephaeline是从ipecac(Cephaelis ipecacuanha [Brot.] A. Rich. [茜草科])中分离出来的一种天然产物。它具有良好的抗肺癌活性,诱导铁变态反应可能是其抗肺癌作用的关键机制:材料与方法:采用 H460 和 A549 肺癌细胞。材料和方法:采用 H460 和 A549 肺癌细胞,用细胞计数试剂盒-8 检测头孢噻肟处理 24 小时后对肺癌细胞的抑制率。此外,在使用西非林(5、10 毫克/千克)治疗 12 天后,还对其体内抗肿瘤效果进行了评估:结果:西法林对肺癌细胞有明显的抑制作用,在 24、48 和 72 小时内,西法林对 H460 和 A549 细胞的 IC50 分别为 88、58 和 35 nM,对 A549 细胞的 IC50 分别为 89、65 和 43 nM。同时,我们还证明了铁突变是头孢菲林抗肺癌的关键机制。最后,我们发现头孢氨苄通过靶向 NRF2 诱导肺癌细胞的铁凋亡:我们首次证明了头孢菲林能抑制 NRF2,从而导致肺癌细胞的铁蛋白沉着。这些发现可能有助于开发治疗肺癌的创新疗法。
{"title":"Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy.","authors":"Peng Chen, Qingxuan Ye, Shang Liang, Linghui Zeng","doi":"10.1080/13880209.2024.2309891","DOIUrl":"10.1080/13880209.2024.2309891","url":null,"abstract":"<p><strong>Context: </strong>Cephaeline is a natural product isolated from ipecac (<i>Cephaelis ipecacuanha</i> [Brot.] A. Rich. [Rubiaceae]). It exhibits promising anti-lung cancer activity and ferroptosis induction may be a key mechanism for its anti-lung cancer effect.</p><p><strong>Objectives: </strong>This study investigates the anti-lung cancer activity and mechanisms of cephaeline both <i>in vitro</i> and <i>in vivo</i>.</p><p><strong>Materials and methods: </strong>H460 and A549 lung cancer cells were used. The cephaeline inhibition rate on lung cancer cells was detected <i>via</i> a Cell Counting Kit-8 assay after treatment with cephaeline for 24 h. Subsequently, the concentrations of 25, 50 and 100 nM were used for <i>in vitro</i> experiments. In addition, the antitumour effects of cephaeline (5, 10 mg/kg) <i>in vivo</i> were evaluated after 12 d of cephaeline treatment.</p><p><strong>Results: </strong>Cephaeline showed significant inhibitory effects on lung cancer cells, and the IC<sub>50</sub> of cephaeline on H460 and A549 at 24, 48 and 72 h were 88, 58 and 35 nM, respectively, for H460 cells and 89, 65 and 43 nM, respectively, for A549 cells. Meanwhile, we demonstrated that ferroptosis is the key mechanism of cephaeline against lung cancer. Finally, we found that cephaeline induced ferroptosis in lung cancer cells by targeting NRF2.</p><p><strong>Discussion and conclusion: </strong>We demonstrated for the first time that cephaeline inhibits NRF2, leading to ferroptosis in lung cancer cells. These findings may contribute to the development of innovative therapeutics for lung cancer.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"62 1","pages":"195-206"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10860416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139712809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of Jian Gan powder on the proliferation, migration and polarization of macrophages and relative mechanism. 建干粉对巨噬细胞增殖、迁移和极化的影响及其机制。
IF 3.8 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-02-07 DOI: 10.1080/13880209.2024.2309864
Kun Li, Xue Zheng, Jian Zhang, Zhanpeng Yan, Yu Ji, Fei Ge, Fangshi Zhu

Context: Jian Gan powder (JGP) is a Chinese medicine compound comprised ginseng, Radix Paeoniae Alba, Radix Astragali, Salvia miltiorrhiza, Yujin, Rhizoma Cyperi, Fructus aurantii, Sophora flavescens, Yinchen, Bupleurum and licorice.

Objective: This study explored the inhibitory effects, polarization and potential mechanisms associated with JGP in macrophages.

Materials and methods: RAW264.7 cells were randomly divided into six groups for 24 h: control, lipopolysaccharide (LPS), overexpression, 1% JGP, 2% JGP, 4% JGP, 8% JGP and 16% JGP. The effects of JGP on RAW264.7 cell proliferation were assessed using colony formation assays and cell counting kit-8 (CCK-8) assays. The Transwell assay was used to evaluate its impact on RAW264.7 cell migration. Moreover, we analysed the interleukin-6 (IL-6)/signal transducer and activator of the transcription 3 (IL-6/STAT3) signaling pathway using quantitative real-time PCR and Western blotting. Furthermore, we examined the M1/M2 polarization levels.

Results: Unlike LPS stimulation, JGP serum treatment markedly suppressed macrophage proliferation and migration capacity, while STAT3 overexpression enhanced RAW264.7 cell proliferation and migration. JGP inhibited the proliferation and migration of RAW264.7 cells by attenuating the IL-6/STAT3 signaling pathway. Furthermore, it inhibited macrophage M1 polarization, promoting M2 polarization.

Discussion and conclusions: JGP effectively suppressed the cellular function of RAW264.7 cells by down-regulating the IL-6/STAT3 signaling pathway and modulating macrophage M1/M2 polarization. These findings provide valuable theoretical and experimental basis for considering the potential clinical application of JGP in the treatment of immune-mediated liver injury in clinical practice.

背景:健胃散是由人参、白芍、黄芪、丹参、郁金、香附、枳壳、槐花、银翘、柴胡、甘草组成的中药复方制剂:本研究探讨了 JGP 对巨噬细胞的抑制作用、极化及潜在机制:将 RAW264.7 细胞随机分为六组,每组 24 h:对照组、脂多糖(LPS)组、过表达组、1% JGP 组、2% JGP 组、4% JGP 组、8% JGP 组和 16% JGP 组。JGP 对 RAW264.7 细胞增殖的影响通过菌落形成试验和细胞计数试剂盒-8(CCK-8)试验进行评估。Transwell 试验用于评估 JGP 对 RAW264.7 细胞迁移的影响。此外,我们还使用定量实时 PCR 和 Western 印迹技术分析了白细胞介素-6(IL-6)/信号转导和转录激活因子 3(IL-6/STAT3)信号通路。此外,我们还检测了 M1/M2 极化水平:结果:与 LPS 刺激不同,JGP 血清处理明显抑制了巨噬细胞的增殖和迁移能力,而 STAT3 的过表达增强了 RAW264.7 细胞的增殖和迁移。JGP 通过抑制 IL-6/STAT3 信号通路来抑制 RAW264.7 细胞的增殖和迁移。此外,它还能抑制巨噬细胞M1极化,促进M2极化:JGP通过下调IL-6/STAT3信号通路和调节巨噬细胞M1/M2极化,有效抑制了RAW264.7细胞的细胞功能。这些发现为JGP在临床上治疗免疫介导的肝损伤提供了宝贵的理论和实验依据。
{"title":"The effect of Jian Gan powder on the proliferation, migration and polarization of macrophages and relative mechanism.","authors":"Kun Li, Xue Zheng, Jian Zhang, Zhanpeng Yan, Yu Ji, Fei Ge, Fangshi Zhu","doi":"10.1080/13880209.2024.2309864","DOIUrl":"10.1080/13880209.2024.2309864","url":null,"abstract":"<p><strong>Context: </strong>Jian Gan powder (JGP) is a Chinese medicine compound comprised ginseng, Radix Paeoniae Alba, Radix Astragali, Salvia miltiorrhiza, Yujin, Rhizoma Cyperi, Fructus aurantii, Sophora flavescens, Yinchen, Bupleurum and licorice.</p><p><strong>Objective: </strong>This study explored the inhibitory effects, polarization and potential mechanisms associated with JGP in macrophages.</p><p><strong>Materials and methods: </strong>RAW264.7 cells were randomly divided into six groups for 24 h: control, lipopolysaccharide (LPS), overexpression, 1% JGP, 2% JGP, 4% JGP, 8% JGP and 16% JGP. The effects of JGP on RAW264.7 cell proliferation were assessed using colony formation assays and cell counting kit-8 (CCK-8) assays. The Transwell assay was used to evaluate its impact on RAW264.7 cell migration. Moreover, we analysed the interleukin-6 (IL-6)/signal transducer and activator of the transcription 3 (IL-6/STAT3) signaling pathway using quantitative real-time PCR and Western blotting. Furthermore, we examined the M1/M2 polarization levels.</p><p><strong>Results: </strong>Unlike LPS stimulation, JGP serum treatment markedly suppressed macrophage proliferation and migration capacity, while STAT3 overexpression enhanced RAW264.7 cell proliferation and migration. JGP inhibited the proliferation and migration of RAW264.7 cells by attenuating the IL-6/STAT3 signaling pathway. Furthermore, it inhibited macrophage M1 polarization, promoting M2 polarization.</p><p><strong>Discussion and conclusions: </strong>JGP effectively suppressed the cellular function of RAW264.7 cells by down-regulating the IL-6/STAT3 signaling pathway and modulating macrophage M1/M2 polarization. These findings provide valuable theoretical and experimental basis for considering the potential clinical application of JGP in the treatment of immune-mediated liver injury in clinical practice.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"62 1","pages":"162-169"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis. 中药注射剂作为宫颈癌辅助疗法在中国患者中的疗效和安全性比较:一项网络荟萃分析。
IF 3.9 3区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-02-09 DOI: 10.1080/13880209.2024.2312217
Fei Ma, Qun Wang, Di Zhang, Zihong Wang, Hui Xie, Xianghong Liu, Hongxing Zhang, Haiyan Song, Shiguang Sun

Context: Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.

Objective: To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).

Materials and methods: Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).

Results: Forty-seven RCTs were included, including nine CMI types: Aidi, Fufangkushen, Huangqi, Kangai (KA), Kanglaite (KLT), Renshenduotang, Shenqifuzheng (SQFZ), Shenmai (SM), and Yadanzi. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.

Conclusions: The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.

背景:在中国,中药注射剂被广泛用于宫颈癌的辅助治疗。然而,不同类型中药注射剂的有效性仍不确定:目的:评估中药注射液与放疗或同步化学放疗(CCRT)联合使用的有效性和安全性,尤其是与顺铂(DDP)、多西他赛加顺铂(DP)和紫杉醇加顺铂(TP)联合使用时的有效性和安全性:从开始到 2023 年 9 月,在 CNKI、万方、VIP、SinoMed、PubMed、Cochrane Library、Embase 和 Web of Science 等数据库中检索了随机对照试验(RCT)。我们计算了临床有效率(CER)、按卡诺夫斯基表现状态(KPS)计算的有效率、白细胞减少率(LRR)和胃肠道反应率(GRR)的风险比(95%置信区间)和累积排名面积曲线下表面(SUCRA):结果:共纳入 47 项 RCT,包括 9 种 CMI 类型:艾迪(Aidi)、复方苦参(Fufangkushen)、黄芪(Huangqi)、康艾(Kangai,KA)、康莱特(Kanglaite,KLT)、仁心堂(Renshenduotang)、神曲扶正(Shenqifuzheng,SQFZ)、神麦(Shenmai,SM)和雅丹子(Yadanzi)。KLT和KA可能分别是CER和KPS放疗的最佳选择。对于 CER 和 GRR,KA 和 KLT 分别是 RT + DDP 的最佳选择。KLT可能是对CER进行RT+DDP治疗的最佳选择,而KA则是对KPS和GRR进行RT+DDP治疗的最佳选择。对于 CER 和 LRR,SM 和 SQFZ 分别是 RT + TP 的最佳选择:最佳推荐方案取决于CMI是与放疗一起使用还是同时进行化放疗。需要更多高质量的 RCT 来进一步确认和更新现有证据。
{"title":"Comparative efficacy and safety of Chinese medicine injections as an adjunctive therapy for cervical cancer in Chinese patients: a network meta-analysis.","authors":"Fei Ma, Qun Wang, Di Zhang, Zihong Wang, Hui Xie, Xianghong Liu, Hongxing Zhang, Haiyan Song, Shiguang Sun","doi":"10.1080/13880209.2024.2312217","DOIUrl":"10.1080/13880209.2024.2312217","url":null,"abstract":"<p><strong>Context: </strong>Chinese medicine injections (CMIs) are widely used as adjuvant therapy for cervical cancer in China. However, the effectiveness of different types of CMIs remains uncertain.</p><p><strong>Objective: </strong>To assess the effectiveness and safety of CMIs when used in conjunction with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in combination with cisplatin (DDP), docetaxel plus cisplatin (DP), and paclitaxel plus cisplatin (TP).</p><p><strong>Materials and methods: </strong>Randomized controlled trials (RCTs) were searched in databases including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science from inception to September 2023. We calculated the risk ratio with a 95% confidence interval and the surface under the cumulative ranking area curve (SUCRA) for the clinical efficacy rate (CER), the efficacy rate by Karnofsky Performance Status (KPS), and the rates of leukopenia reduction (LRR) and gastrointestinal reactions (GRR).</p><p><strong>Results: </strong>Forty-seven RCTs were included, including nine CMI types: <i>Aidi</i>, <i>Fufangkushen</i>, <i>Huangqi</i>, <i>Kangai</i> (KA), <i>Kanglaite</i> (KLT), <i>Renshenduotang</i>, <i>Shenqifuzheng</i> (SQFZ), <i>Shenmai</i> (SM), and <i>Yadanzi</i>. KLT and KA were likely optimal choices with radiotherapy for CER and KPS, respectively. KA and KLT were optimal choices with RT + DDP for CER and GRR, respectively. KLT was the likely optimal choice with RT + DP for CER and KA for both KPS and GRR. SM and SQFZ were the likely optimal choices with RT + TP for CER and LRR, respectively.</p><p><strong>Conclusions: </strong>The optimal recommendation depends on whether CMIs are used with radiotherapy or concurrent chemoradiotherapy. More high-quality RCTs are needed to confirm further and update the existing evidence.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"62 1","pages":"170-182"},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10860435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmaceutical Biology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1